Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT

  • STATUS
    Recruiting
  • End date
    Feb 28, 2023
  • participants needed
    80
  • sponsor
    University Of Perugia
Updated on 23 January 2021
cancer
remission
chronic myeloid leukemia
stem cell transplantation
graft versus host disease
myeloid leukemia
lymphoid leukemia
hematologic malignancy
chronic lymphocytic leukemia
lymphoma
multiple myeloma
hodgkin's disease
acute leukemia
cell transplantation
myeloablative conditioning
leukemia
myeloproliferative syndromes

Summary

To evaluate if hyper-fractionated TBI or TMLI followed by Treg/Tcon adoptive immunotherapy improve cGvHD/disease free survival after allogeneic HSCT in patients affected by high-risk acute leukemias or other hematologic malignancy where HSCT is indicated.

Description

Improving cGvHD/disease free survival in patients with high-risk acute leukemias or other hematologic malignancy where HSCT is indicated with the use of a regulatory T cell based protocol. Hyper-fractionated Total Body Irradiation or Total Marrow and Lymphoid Irradiation based conditioning will be followed by the infusion of T regulatory and T conventional cell adoptive immunotherapy and a purified CD34+ hematopoietic stem cell graft. Incidence of Non Relapse Mortality, Relapse, acute Graft versus Host Disease, chronic Graft versus Host Disease, as well as probability of cGvHD/disease free survival will be assessed in patient subpopulations separated according to HLA-matching with the donor (HLA-matched HSCT and HLA-haploidentical HSCT) and type of disease (acute myeloid leukemia, acute lymphoid leukemia, lymphoma, multiple myeloma, myeloproliferative disease, and other).

Details
Condition Bone marrow disorder, childhood ALL, Hematologic Malignancy, Multiple Myeloma, Lymphoma, Acute myeloid leukemia, Lymphoproliferative Disorder, Lymphoma, MYELOPROLIFERATIVE DISORDER, Non-Hodgkin's Lymphoma, Acute Myelogenous Leukemia (AML), Myeloproliferative Neoplasms, Lymphocytic Leukemia, Acute, Blood Cancer, Hematologic Cancer, Hematologic Neoplasms, Lymphoproliferative disorders, Other Hematologic Malignant Neoplasms, leukemia, acute lymphoblastic, myeloproliferative neoplasm, myeloproliferative disorders, lymphomas, multiple myeloma (mm), acute lymphoid leukaemia, acute lymphocytic leukemia, acute lymphoblastic leukemia (all), acute myelogenous leukemia, anll, acute myeloblastic leukemia
Treatment High dose irradiation conditioning + Treg/Tcon
Clinical Study IdentifierNCT03977103
SponsorUniversity Of Perugia
Last Modified on23 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age less than or equal to 75 yrs?
Gender: Male or Female
Do you have any of these conditions: Bone marrow disorder or Non-Hodgkin's Lymphoma or Lymphoproliferative Disorder or childhood ALL or Lymphoma or Acute Myelogenous Leukemia (AML) or Lym...?
Do you have any of these conditions: myeloproliferative neoplasm or Hematologic Malignancy or multiple myeloma (mm) or Hematologic Cancer or lymphomas or Acute Myelogenous Leukemia (AML) ...?
AML and ALL in complete remission and with high-risk of relapse
AML and ALL primarily chemoresistant or relapsed
Chronic Myeloid Leukemia in accelerated or blastic phase
Patients affected by
Multiple myeloma
Non Hodgkin lymphoma
Hodgkin lymphoma
Chronic myeloproliferative syndrome
Chronic Lymphoid Leukemia
Other Hematological malignancy at high-risk of relapse or detectable disease and where a HSCT is indicated
Age <75 years
ECOG 2
Acceptable lung, liver, kidney, and heart function and absence of relevant psichiatric diseases
Signature of the informed consent

Exclusion Criteria

Age >75 years
ECOG > 2
Not acceptable lung, liver, kidney, and heart function and presence of relevant psichiatric diseases
Pregnancy
No signature of the informed consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note